Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.58
NBS's Cash to Debt is ranked higher than
57% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. NBS: 1.58 )
NBS' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1.58

Equity to Asset 0.46
NBS's Equity to Asset is ranked higher than
60% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NBS: 0.46 )
NBS' s 10-Year Equity to Asset Range
Min: -19.52   Max: 0.88
Current: 0.46

-19.52
0.88
F-Score: 3
Z-Score: -3.31
M-Score: -2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -321.86
NBS's Operating margin (%) is ranked higher than
62% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. NBS: -321.86 )
NBS' s 10-Year Operating margin (%) Range
Min: -10991.67   Max: -27.04
Current: -321.86

-10991.67
-27.04
Net-margin (%) -305.87
NBS's Net-margin (%) is ranked higher than
62% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. NBS: -305.87 )
NBS' s 10-Year Net-margin (%) Range
Min: -13154.35   Max: -33.38
Current: -305.87

-13154.35
-33.38
ROE (%) -85.27
NBS's ROE (%) is ranked higher than
58% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. NBS: -85.27 )
NBS' s 10-Year ROE (%) Range
Min: -578.99   Max: -57.05
Current: -85.27

-578.99
-57.05
ROA (%) -48.37
NBS's ROA (%) is ranked higher than
62% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. NBS: -48.37 )
NBS' s 10-Year ROA (%) Range
Min: -850.61   Max: -18.34
Current: -48.37

-850.61
-18.34
ROC (Joel Greenblatt) (%) -390.55
NBS's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. NBS: -390.55 )
NBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80050   Max: -46.95
Current: -390.55

-80050
-46.95
Revenue Growth (3Y)(%) -21.30
NBS's Revenue Growth (3Y)(%) is ranked higher than
66% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NBS: -21.30 )
NBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 196.7
Current: -21.3

0
196.7
EBITDA Growth (3Y)(%) -22.40
NBS's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NBS: -22.40 )
NBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.8   Max: 14.3
Current: -22.4

-56.8
14.3
EPS Growth (3Y)(%) -24.50
NBS's EPS Growth (3Y)(%) is ranked higher than
64% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NBS: -24.50 )
NBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 9.6
Current: -24.5

-52.7
9.6
» NBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBS Guru Trades in

NBS Guru Trades in

Q3 2013

NBS Guru Trades in Q3 2013

Jim Simons 30,037 sh (New)
» More
Q4 2013

NBS Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
NBS's P/B is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. NBS: 1.90 )
NBS' s 10-Year P/B Range
Min: 0.59   Max: 150
Current: 1.9

0.59
150
P/S 5.17
NBS's P/S is ranked higher than
83% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. NBS: 5.17 )
NBS' s 10-Year P/S Range
Min: 0.72   Max: 360.71
Current: 5.17

0.72
360.71
EV-to-EBIT -1.51
NBS's EV-to-EBIT is ranked higher than
68% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NBS: -1.51 )
NBS' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: -0.2
Current: -1.51

-8.1
-0.2
Current Ratio 2.23
NBS's Current Ratio is ranked higher than
60% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. NBS: 2.23 )
NBS' s 10-Year Current Ratio Range
Min: 0.02   Max: 5.54
Current: 2.23

0.02
5.54
Quick Ratio 2.23
NBS's Quick Ratio is ranked higher than
63% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NBS: 2.23 )
NBS' s 10-Year Quick Ratio Range
Min: 0.02   Max: 5.54
Current: 2.23

0.02
5.54
Days Inventory 23.98
NBS's Days Inventory is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NBS: 23.98 )
NBS' s 10-Year Days Inventory Range
Min: 15.69   Max: 457.38
Current: 23.98

15.69
457.38
Days Sales Outstanding 63.30
NBS's Days Sales Outstanding is ranked higher than
83% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. NBS: 63.30 )
NBS' s 10-Year Days Sales Outstanding Range
Min: 26.85   Max: 4506.17
Current: 63.3

26.85
4506.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
NBS's Dividend Yield is ranked lower than
81% of the 228 Companies
in the Global Biotechnology industry.

( Industry Median: 1.03 vs. NBS: 0.40 )
NBS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Dividend growth (3y) -100.00
NBS's Dividend growth (3y) is ranked higher than
67% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. NBS: -100.00 )
NBS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -100
Current: -100

Yield on cost (5-Year) 0.40
NBS's Yield on cost (5-Year) is ranked lower than
80% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 1.22 vs. NBS: 0.40 )
NBS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Share Buyback Rate -54.60
NBS's Share Buyback Rate is ranked higher than
56% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: -9.60 vs. NBS: -54.60 )
NBS' s 10-Year Share Buyback Rate Range
Min: -14.5   Max: -150.6
Current: -54.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
NBS's Price/Median PS Value is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. NBS: 0.40 )
NBS' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 18.75
Current: 0.4

0.08
18.75
Earnings Yield (Greenblatt) -69.10
NBS's Earnings Yield (Greenblatt) is ranked lower than
69% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. NBS: -69.10 )
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -69.1   Max: 0
Current: -69.1

-69.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8NE1.Germany,
Neostem Inc was incorporated under the laws of the State of Delaware on September 18, 1980. It is engaged in cellular therapy industry. The Company develops novel proprietary cell therapy products. It is engaged in therapies that addresses ischemia through its CD34 Cell Program. AMR-001 is its product candidate in the CD34 Cell Program being developed to treat damaged heart muscle following an acute myocardial infarction. The Company competes with various companies like Lonza Group Ltd. and WuXi AppTec. The Company is subject to various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services.
» More Articles for NAS:NBS

Headlines

Articles On GuruFocus.com
"New To The Street"Announces Nationwide Broadcast Dec 03 2014 

More From Other Websites
NeoStem Announces Extension of Study Under Grant from California Institute of Regenerative Medicine... Apr 10 2015
NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine... Apr 09 2015
NeoStem to Present at Multiple April Conferences Apr 06 2015
NeoStem to Present at Multiple April Conferences Apr 06 2015
NeoStem (NBS) Enters Oversold Territory - Tale of the Tape Mar 31 2015
NeoStem, Inc. - "CEO Letter to Shareholders" Mar 19 2015
NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results Mar 16 2015
NEOSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure Mar 16 2015
NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results Mar 16 2015
NeoStem to Present at Two Upcoming Investor Conferences in March Mar 12 2015
NeoStem to Present at Two Upcoming Investor Conferences in March Mar 12 2015
NEOSTEM, INC. Financials Mar 11 2015
NeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of... Mar 05 2015
10-K for NeoStem, Inc. Mar 04 2015
NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update Mar 02 2015
NEOSTEM, INC. Files SEC form 10-K, Annual Report Mar 02 2015
NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update Mar 02 2015
NeoStem to Present at BIO CEO & Investor Conference and at Sachs Associates Cancer Bio Partnering &... Feb 05 2015
NeoStem to Present at BIO CEO & Investor Conference and at Sachs Associates Cancer Bio Partnering &... Feb 05 2015
NEOSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jan 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK